anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Apparatus and associated methods relate to presenting for selection services comprising at least one bundled set of healthcare services to be performed separately by respective providers, determining a bundle price for the at least one bundled set of healthcare services, and in response to receiving payment in an amount of the bundle price, generating a persistent purchase data record selectively redeemable to receive each of the at least one bundled set of healthcare services, and assigning a unique confirmation number generated for the purchase data record. The received payment may be a virtual funds payment. The bundle price may be discounted. The bundle price may be based on the location or time at which at least one service will be performed. The bundle price may be based on the user&#39;s remaining health insurance deductible. Payment may be disbursed to multiple providers of the bundled set of healthcare services. Disbursed payment may be virtual funds.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a functional food having sufficient preventive and therapeutic effects to diabetic disease, having no side effect (on both of prolonged administration and short term administration) and sufficiently certified safety, and to provide a functional food which a healthy person can daily take so as not to suffer from diabetic disease, that is, a functional food only suppressing blood glucose level abnormal increase, accompanying no side effect and aiming prevention of diabetic disease.  &lt;P&gt;SOLUTION: An antidiabetic food containing saps of Betulaplatyphylla var. japonica and/or extracts of Inonotus obliquus is provided. As the functional food contains saps of Betulaplatyphylla var. japonica and/or extracts of Inonotus obliquus, so the food exerts excellent suppressing effect of blood glucose level increase and, as a result, exerts sufficient preventive and therapeutic effects to diabetic disease.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PURPOSE:To produce a patch uniformly mixable, having excellent water vapor transmission and low irritation to skin. CONSTITUTION:A tacky agent composition comprising 100 pts.wt. tacky agent, 1-75 pts.wt. one or more selected from a group consisting of ethyl cellulose powder, crystal cellulose powder cellulose acetate powder, cross-linking type polyvinylpyrrolidone powder which is composed of N-vinyl-2-vinylpyrrolidone and a polyfunctional monomer and has &gt;=0.5 gel fraction and a cross-linking type polymer powder cross-linked with a cross-linking agent, having 1-200mum particle diameter, 1-75 pts.wt. polyhydric alcohol and 0.1-50 pts.wt. medicine is applied to one side of a substrate having water vapor transmission by a hot-melt coater to produce a patch.
PURPOSE:To make it possible to manufacture with extreme simplicity a bioactive apatite membrane which is similar to a bone in an organism without performing heat treatment by a method wherein a base material and a glass wherein CaO and SiO2 are at least main ingredients are faced each other in a definite distance or less; the glass ingredient is eluted and a membrane of hydroxyapatite which is similar to the bone is formed on the surface of the main material by immersing in an aq. soln. which is unsatd. to hydroxyapatite. CONSTITUTION:At least main ingredients consist of CaO and SiO2. It is pref. that CaO is 20-70mol%; SiO2 is 30-80mol%; the total of CaO and SiO2 is 65mol% or more. When such a glass that does not contain P2O5 and contains CaO and SiO2 as the main ingredients is used, it is necessary that the water solution contains phosphorus ion which is a main constituting ingredient of apatite. In addition, when such a glass that contains P2O5 and CaO and SiO2 as the main ingredients is used, it is not necessary that the water solution contains phosphorus ion which is a main constituting ingradient of apatite. In addition, when such a glass that contains CaO and, SiO2 as the main ingredients and additionally contains P2O5 is used as a glass, the water solution is selected within a range of 0-0.1mM Ca&lt;2+&gt; and 0-5,000mM HPO4&lt;2-&gt;.
The invention belongs to the technical field of medicinal and edible formula foods, and in particular relates to pleasing essential oil. Poor mental state is due to the factors of excessive tension, lack of sleep, overstrain of nerves and irregular resting time. &#39;Homology of medicine and food&#39; is one of the most valuable contributions to human beings in the traditional Chinese medicine, is beneficial to human beings without harm due to &#39;neutral&#39; property, and is a most major standard for selecting foods in the traditional Chinese medicine. The standard is established on the basis of &#39;people first&#39;. According the traditional Chinese medicine, the emphasis is put on the theory that &#39;medical therapy is inferior to oil smearing therapy&#39;, and the aim is to condition, prevent and resist fatigue. Multiple natural and ecological medicinal and edible foods are added according to the fatigue physical characteristic on the basis of inheriting the valuable disease treatment method in traditional Chinese medicine. The unique advantages of oil smearing therapy, prevention and conditioning are integrated.
The invention provides &#39;doctor dependent selective data compression&#39;. An apparatus includes a network interface and a processor. The network interface is configured to communicate over a communication network. The processor is configured to receive (i) data including a medical parameter acquired as a function of time, and (ii) a selection of one or more time intervals of interest over a period of time. The processor is further configured to: compressing a first portion of data within a selected time interval at a first resolution; and compressing a second portion of the data outside the selected time interval at a second resolution coarser than the first resolution. The processor is additionally configured to transmit the compressed first portion and the compressed second portion of the data over the communication network via the network interface.
Have the invention discloses one kind and treating infectious bronchitis of chicken eupatorium lindleynun var. trifoliolatum granule, the eupatorium lindleynun var. trifoliolatum granule major ingredient includes by weight：35~55 parts of eupatorium lindleynun var. trifoliolatum, 20~40 parts of radix scutellariae, 15~35 parts of Fructus Forsythiae, 15~30 parts of campanulaceae, 10~20 parts of Radix Glycyrrhizae；The auxiliary material of eupatorium lindleynun var. trifoliolatum granule includes 3~6 parts of corrigent, 5~10 parts of sweetener, 20~30 parts of forming agent by weight；There should be treatment infectious bronchitis of chicken eupatorium lindleynun var. trifoliolatum granule, eupatorium lindleynun var. trifoliolatum thick paste is fabricated to by particle using forming agent, the bitter taste in eupatorium lindleynun var. trifoliolatum is set to include, it is allowed to not show bitter taste under the premise of not losing ingredient and not affecting the treatment, significantly improve the mouthfeel of preparation, not only it had avoided with a large amount of sucrose flavor adjustments, but also has reduced preparation loading amount；The present invention&#39;s has treatment infectious bronchitis of chicken with eupatorium lindleynun var. trifoliolatum granule compared with syrup, and administering mode is the same, is oral medication, and good absorbing is proved effective fast, and curative for effect consistent, toxic side effect is small, highly practical, use easy to spread.
The invention relates to compounds of the structure &lt;FORM:0998294/C2/1&gt; wherein X is Cl or F, A is CH3 or H, Z is Cl,Br or H but when X is F and A is CH3, Z is H and E is H or OH, provided that when E is OH, A is CH3 and Z is H by chlorination or fluorination of compounds of the structure &lt;FORM:0998294/C2/2&gt; in a reaction inert solvent.  The products of the invention may exist as cis or trans isomers at the 11a-position, the cis isomer being non-ketalized. Specified chlorinating agents are chlorine, iodochloride, N-chloro-lower alkanoic acid amides, N-chlorinated hydrocarbon dicarboxylic acid imides and N-chlorinated-lower-alkanoyl anilides, 3,5-dichloro-5,5-dimethyl-hydantoin, pyridinium perchloride hydrohalides and lower alkyl hypochlorites, wherein lower means containing 1 to 5 carbon atoms.  A specified fluorinating agent is perchloryl fluoride in the presence of a strong base.  At temperatures above 50 DEG  C. formation of the 5a,6-anhydro compounds may occur.  The products of the invention may be (1) halogenated and/or nitrated in the 7 and/or 9 positions by a halogenating agent and/or nitric acid or (ii) coupled with aryl diazonium salts at the 7 and/or 9 positions.  These nitro and azo compounds may be reduced to the corresponding amino compounds, e.g. by catalytic hydrogenolysis. The 11a-halogen atoms of the tetracyclines of the invention may be selectively removed by reduction, e.g. with aqueous sodium hydrosulphite, zinc in mineral acid or hydrogenolysis over noble metal catalysts, in the latter reaction other groups may be reduced. Acid addition salts of the tetracycline compounds are prepared by reaction with the appropriate acid e.g. hydrochloric acid, sulphuric acid, hydrobromic acid and phosphoric acid.  Specification 995,033 also is referred to.
The freeze-dried herb mat (1) for cosmetic treatment, comprises two layers (2, 3) that are made of a planar non-woven textile structure and that are included in between an intermediate space, which is sub divided into chambers (5, 8) filled with herbs by lock stitch seams (4). Each adjacent chamber is separated from each other by an area (10) that is not filled with herbs. The area that is not filled with herbs is separated without destroying the adjacent chambers. The lock stitch seams connects the layers together that are arranged one above the other. The freeze-dried herb mat (1) for cosmetic treatment, comprises two layers (2, 3) that are made of a planar non-woven textile structure and that are included in between an intermediate space, which is sub divided into chambers (5, 8) filled with herbs by lock stitch seams (4). Each adjacent chamber is separated from each other by an area (10) that is not filled with herbs. The area that is not filled with herbs is separated without destroying the adjacent chambers. The lock stitch seams connects the layers together that are arranged one above the other. The formed chambers do not exhibit larger dimensions than the area filled with herbs. Double lock stitch seams run constantly from an edge of the herb mat up to opposite or adjacent edge of the herb mat. The chambers are limited by seams, which form closed circles/squares. The areas that are not filled with herbs are provided with a perforation. The perforation extends from an edge of the herb mat up to an opposite or adjacent edge. The chambers are formed in the form of polygon by an irregular arrangement of double lock stitch seams. The intermediate space is filled with herb mixture from chamomile, horsetail, lady&#39;s mantle, rosemary and yarrow. Two groups of lock stitch seams exhibit in each case different direction. The double lock stitch seams belonging to two different groups cross each other.
An effective amount of perfume/cyclodextrin complex is applied to fabric that is preferably at least partially wetted. A preferred method applies said complex to said fabric in an automatic laundry dryer. The perfume/cyclodextrin complexes are preferably incorporated into solid, dryer-activated, fabric treatment (conditioning) compositions, preferably containing fabric softeners, more preferably cationic and/or nonionic fabric softeners. The complexes provide fabrics with perfume benefits when they are rewetted after drying. Volatile perfume materials including those materials that are commonly associated with &#34;freshness&#34; can be applied to the fabrics in an effective way. Clay provides protection for said perfume/cyclodextrin complexes, especially when certain materials like some nonionic fabric softeners and/or fatty acids are present and in contact with said perfume/cyclodextrin complexes.
PROBLEM TO BE SOLVED: To prevent a materials that composes a blank of an artificial tooth from changing by processing and use or changing with time and to maintain its original shape and volume by forming the blank out of a plastic reinforced with glass fibers. SOLUTION: The blank 10 is made from a plastic material 12 of partly aromatic polyamide that is reinforced by fragments of cast glass fiber 14. The plastic material 12 consists of the glass fiber 14 that are aligned or not aligned according to the demand for each artificial tooth by a special method for casting production. The blank 10 can gain modulus of elasticity in tension of 22 GPa and Brinell hardness of 280 Mpa. Its breaking load is about 1,150 N without being added by an addition. It is right as its specific gravity is about 1.7 g per cubic cm. Moreover, as it is a bad conductor for heat, clients&#39; dissatisfaction caused by heat conduction would not be occurred. Also, from the viewpoint of aesthetic, it has the semi-translucent color like tooth enamel and it can be transmitted by lights.
PURPOSE:To obtain a compound having thromboxane A2 antagonistic action and useful as a platelet aggregation suppressing agent by reducing an indane derivative and condensing with a sulfonic acid. CONSTITUTION:The objective compound of formula II can be produced by reducing a compound of formula I (R&lt;1&gt; is -SO3R or H; R is phenyl, naphthyl or sulfur-containing heterocyclic group; R&lt;2&gt; is H or lower alkyl; R&lt;3&gt; is lower alkoxycarbonyl-lower alkyl, etc.; Y is phenylmercaptomethylene, lower alkylmercaptomethylene, carbonyl, etc.) or its salt to convert the group Y into methylene group and, when R&lt;1&gt; is H, condensing the reduction product with a sulfonic acid compound of formula RSO3H or its reactive derivative. The starting compound of formula I is novel compound which can be produced by condensing a compound of formula III (R&lt;11&gt; is -SO2R or amino-protecting group) with a compound of formula IV (Y&lt;1&gt; is phenylmercaptomethylene, etc.; X is halogen).
NEW MATERIAL:A compound expressed by the formula (R represents glycoside group and/or galactosyl group; n is an integer of &gt;=1). USE:An additive for foods and antitumor agent. PREPARATION:For example, sesame seeds are previously defatted, pulverized into less than 100 meshes, immersed in a water-methanol based solvent and agitated while heating to carry out extraction. A crude glycoside is obtained by vaporizing the solvent therefrom. The crude glycoside is then dissolved in chloroform and an equal amount of water is added thereto and vigorously stirred. A chloroform phase is separated therefrom and the solvent is distilled off to afford a chloroform-soluble fraction. Then acetone is added thereto, and after stirring, a supernatant liquid is removed to separate an acetone- insoluble fraction. The product is purified by column chromatography with a chloroform-methanol based solvent and a silica gel column, etc., to afford the compound expressed by the formula.
PROBLEM TO BE SOLVED: To obtain a soft capsule film excellent in solubility, adhesion resistance and appearance, without mutual adhesion and adhesion to a storage vessel and capable of obtaining soft capsule formulations having good appearance by adding silk. SOLUTION: A soft capsule film is obtained by adding silk. This soft capsule film is preferably obtained by adding silk to a film base material such as gelatin. The silk is a type of amino acids having 90 average molecular weight and &gt;=5 wt.%, preferably 2 wt.% of silk of the amino acid type is added to the gelatin. The silk is preferably a peptide type having 500 average molecular weight and a protein type having 1-5 μm average size. The amino acid type adopted as the silk is obtained by thoroughly hydrolyzing silk fiber, the peptide type is obtained by hydrolyzing silk fiber to a certain degree and the protein type is obtained by mechanically pulverizing silk fiber.
PURPOSE:To obtain the title substance by allowing an acylating agent to act on 6-acyl-7-deacetylforskolin derivative into a 1,6,7-triacyl derivative (a novel substance), then removing the acyl group in the 1-position by solvolysis. CONSTITUTION:An acylating agent such as acetic anhydride (2-4 fold moles) is allowed to act on a compound of formula I (R&lt;2&gt; is acyl; R&lt;3&gt; is 2-3C hydrocar bon group) at 0 deg.C to room temperature for several minutes to 2hr to form 1,6,7-triacyl-7-deacetylforskolin derivative (a novel substance) of formula II. Then, the product is preferably hydrolyzed to give a compound of formula III. The hydrolysis is carried out in a solvent in the presence of a base or acid at 0 deg.C to room temperature for 5min-3hr. The solvent is preferably an aqueous alcohol of 1-4C carbon atoms, containing 0.5-20V/V% of water. Thus, the compound of formula III which is expectantly used as a medicines is obtained in high yield.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a technique for exhibiting protective actions on cardiac muscles or blood vessels from peroxide damage by activating protein kinase C without adverse effects and to provide a protein kinase C activator.  &lt;P&gt;SOLUTION: The protein kinase C activator comprises the following glycoprotein. (1) present in royal jelly and forming a single band in an unmodified polyacrylamide gel electrophoresis, (2) having about 57 kDa molecular weight measured by an SDS-polyacrylamide gel electrophoresis under reducing conditions and (3) containing an amino acid sequence of amino acid numbers 1-8 of sequence number 1 (refer to the specification). A composition is obtained by including the protein kinase C activator in a composition for oral administration. Thereby, the technique for exhibiting the protective actions on the cardiac muscles or blood vessels from the peroxide damage by activating the protein kinase C without the adverse effects can be provided.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PURPOSE: To obtain an adenosine antagonistic agent, containing a new pyrazolopyridine compound or its salt as an active ingredient and useful for preventing or treating a depressive state, cardiac insufficiency, hypertension, renal insufficiency, nephritis, bronchial asthma, diabetes, etc. CONSTITUTION: This medicine contains a pyrazolopyridine compound of formula I [R&lt;1&gt; is an aryl; R&lt;2&gt; is an acyl-(lower) alkyl; A is a lower alkenylene]  e.g. (2R)-1-[3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-(methoxycar bonylmethyl) piperidine} or its salts as an active ingredient. Furthermore, the compound of formula I is obtained by reacting, e.g. a compound of formula II with a compound of formula III in an inert solvent in the presence of a condensing agent. The daily dose of the compound of formula I is 0.01-100mg per kg body weight in the case of intravenous and intramuscular administrations and 0.01-200mg per kg body weight in the case of oral administration.
PURPOSE: To obtain the subject contrast medium containing a specific brominated perfluorocarbon as an active ingredient, excellent in X-ray shielding properties, having a low accumulating property in the living body, no toxicity and an excellent living body adaptability. CONSTITUTION: This X-ray contrast medium contains a brominated perfluorocarbon of formula I [R&lt;1&gt; , R&lt;2&gt; are each a 2-5C perfluoroalkyl or a ring structure formed by linking the part of formula II in one unit; A is -(CF2 )n - (n is 1-5)], or formula III (R&lt;3&gt; , R&lt;5&gt; are each F or a 1-3C perfluoroalkyl; R&lt;4&gt; is F, Br) as an active ingredient. The object contrast medium is e. g. in the case of imaging an artery or a vein in extremities, injected percutaneously into the artery or the vein. In the case of imaging vena cava or branching arteries in chest or abdominal parts, it is injected e.g. through a percutaneous arterial catheter. In the case of imaging blood vessels in heart or lung, it is injected e. g. through an intracardiac catheter. For the imaging liver, spleen or tumor, it is preferable to inject it intravenously.  Further, the amount of a dose is preferably 5-500ml for one administration.
Disclosed is a method for evaluating the effectiveness of a health programme. The method includes: (i) selecting type of activity on a computer; (ii) entering and awarding scores for each activity on a computer; (iii) analysing the scores by a computer programme; (iv) recording activity periodically on the computer; (v) recording results of the health programme; (vi) analysing results of programme; and (vii) evaluating the results. Evaluating the results includes monitoring the effectiveness of the health programme by recording daily activities and entering a score for each activity. The score for each activity is based on a set of daily challenges consisting of the following: (i) to undertake &gt;30 minute exercise; (ii) to complete flexibility exercises; (iii) to eat a healthy breakfast; (iv) to eat a wholesome lunch; (v) to eat a balanced dinner; (vi) to eat only healthy (or no) snacks; (vii) to consume no alcohol or drugs; (viii) to not smoke; (ix) to spend &gt; 30 minutes with ones family; and (x) to spend &gt; 30 minutes for/on oneself. The score records a point for each uncompleted activity over 7 days each week over a series of weeks, then the score is recorded as an average for each week. The method also includes: (viii) processing the results to generate the score card wherein the score recorded over a series of weeks is represented in graphic form.
PURPOSE:To depress a melting point and a gel point of an aqueous gel of carrageenan or furcellaran without damaging properties such as elasticity, taste, etc. and to save heat and operation time, by adding a specific amount of a sodium phosphate to an aqueous gel of carrageenan or furcellaran, blending them uniformly. CONSTITUTION:An aqueous gel of carrageenan and/or furcellaran is blended uniformly with a sodium phosphate (e.g., sodium hexametaphosphate, sodium pen tapolyphosphate, etc.) in an amount to give &lt;=twice (preferably 2-1/50 times) that of the aqueous gel as an auxiliary to depress a melting point, so that the melting point of the gel is depressed. EFFECT:A melting point of a mixture of the aqueous gel, fruit juice, coffee, etc. is raised higher than the melting point of the natural melting point, but the degree of the rise is suppressed to the minimum. This aqueous gelations substance is easily released from a container and its shape slightly collapses.
PURPOSE: To obtain a medicine containing a tetrahydroacridine derivative as an active ingredient and used for treating acquired immunodeficiency syndrome. CONSTITUTION: This medicine contains a compound of the formula (X is H, a lower alkyl, a halogen; R is H, a lower alkyl, benzyl), e.g. 9-amino-1,2,3,4- tetrahydroacridin-1-ol as an active ingredient in an amount of 4-70wt.%. The compound is effective for the treatment of HIV infection and has advantageousness substantially superior to tacrine with respect to side effects such as acute toxicity. The compound is further useful for the treatments of hypomnesia characterized by colipurinergic deficiency, such as Alzheimer&#39;s disease. The compound is prepared in the form of capsules, tablets, troches, sterilized solutions, suspensions, etc., and administered orally at a dose of 10-300mg and parenterally at a dose of 0.5-100mg.